Scholarlink

Purpose <p>To evaluate the long-term benefit of early targeted panretinal photocoagulation (PRP) combined with anti-VEGF therapy (IVL group) versus anti-VEGF monotherapy (IV group) in treatment-naïve eyes with macular edema (ME) secondary to ischemic RVO.</p> Methods <p>A retrospective analysis of 143 patients (85 IVL, 58 IV) with ischemic RVO. Baseline ischemic index (IsI), central retinal thickness (CRT), best-corrected visual acuity (BCVA), and age were adjusted.</p> Results <p>Over 48 months, the IVL group showed a reduction in mean CRT from 475.6 ± 117.3&#xa0;μm to 282.0 ± 69.5&#xa0;μm and improved BCVA from 0.61 ± 0.34 LogMAR to 0.44 ± 0.34 LogMAR. The IV group demonstrated CRT reduction from 479.4 ± 135.5&#xa0;μm to 340.9 ± 127.3&#xa0;μm and BCVA improvement from 0.58 ± 0.32 LogMAR to 0.50 ± 0.43 LogMAR. The IVL group received 26.0 ± 8.6 intravitreal anti-VEGF treatments (IVT), compared to 25.5 ± 6.2 IVT in the IV group.</p> Conclusions <p>The IVL group exhibited a trend toward better treatment response, particularly in patients with severe retinal ischemia, though findings were not statistically significant. Baseline IsI quantification is recommended for optimal RVO management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Potential sustained benefits of early targeted panretinal photocoagulation in combination with anti-VEGF in macular edema secondary to retinal vein occlusion: 48-month results of a retrospective comparative study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月13日

查看全文
  • Adnan Kilani,
  • Koray Bayhan,
  • Efstathios Vounotrypidis,
  • Denise Vogt,
  • Almut Bindewald-Wittich,
  • Benjamin Mayer,
  • Christian Enders,
  • Armin Wolf

摘要

Purpose

To evaluate the long-term benefit of early targeted panretinal photocoagulation (PRP) combined with anti-VEGF therapy (IVL group) versus anti-VEGF monotherapy (IV group) in treatment-naïve eyes with macular edema (ME) secondary to ischemic RVO.

Methods

A retrospective analysis of 143 patients (85 IVL, 58 IV) with ischemic RVO. Baseline ischemic index (IsI), central retinal thickness (CRT), best-corrected visual acuity (BCVA), and age were adjusted.

Results

Over 48 months, the IVL group showed a reduction in mean CRT from 475.6 ± 117.3 μm to 282.0 ± 69.5 μm and improved BCVA from 0.61 ± 0.34 LogMAR to 0.44 ± 0.34 LogMAR. The IV group demonstrated CRT reduction from 479.4 ± 135.5 μm to 340.9 ± 127.3 μm and BCVA improvement from 0.58 ± 0.32 LogMAR to 0.50 ± 0.43 LogMAR. The IVL group received 26.0 ± 8.6 intravitreal anti-VEGF treatments (IVT), compared to 25.5 ± 6.2 IVT in the IV group.

Conclusions

The IVL group exhibited a trend toward better treatment response, particularly in patients with severe retinal ischemia, though findings were not statistically significant. Baseline IsI quantification is recommended for optimal RVO management.